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Practical early cancer detection: distinguishing stable from
unstable genomes in pre-cancerous tissues
Sarah Killcoyne 1,2 and Rebecca C. Fitzgerald 1
Barrett’s oesophagus has been known for many years to display early changes to the genome consistent with the risk for
oesophageal adenocarcinoma. Recently we have shown that this information can be used without knowledge of individual gene
mutations to accurately predict a patient’s future risk of malignant progression.
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MAIN
Early detection of cancer offers individual patients the best chance
of long-term survival, and improved quality of life since treatment
is usually less invasive. This is the driving force behind screening
initiatives, and researchers’ continual efforts to refine our under-
standing of patient risk. Large genomic sequencing efforts in the
last decade have provided molecular evidence that carcinogenesis
occurs over many years,1 and that genetic mutations predisposing
a patient to cancer may be found in physiologically normal
tissues.2,3 This has offered positive evidence that genomics can
offer a route to early detection of cancers. However, early
detection must be balanced with overdiagnosis in pre-cancerous
tissues that are unlikely to ever become malignant.
One of the difficulties in implementing early detection screen-
ing based on molecular data is the accessibility of pre-cancerous
tissues, especially those where longitudinal samples could provide
time-specific information showing transformation or stability.
Lesions that are easy to access, such as skin, may also be easier
to treat than observe, while tissues that require highly invasive
clinical sampling methods (i.e. prostate needle biopsies) are going
to be more difficult tissues from which to generate longitudinal
data. Current methods for surveillance of the oesophagus involves
sampling easily identifiable pre-malignant tissue over long periods
of time. In the oesophageal premalignancy, called Barrett’s
oesophagus, surveillance and early detection has focused on
clinical risk stratification (i.e. patient age, length of the Barrett’s
segment) and histopathology of the tissue.4 Considering the low
annual risk of histopathological transformation, it is likely that
many patients are undergoing invasive procedures unnecessarily.
Improving our understanding of patient risk in the context of
oesophageal cancer has led to a number of efforts to identify
sensitive biomarkers. Early genomics work5 showed that the
genomes of Barrett’s tissues could display significant copy number
changes, and subsequent studies confirmed aneuploidy and
cellular clonality6,7 as features of malignant transformation. These
led to attempts at patient stratification using immunohistochem-
istry biomarkers, measures of aneuploidy, panels of gene
mutations,8 or methylation markers.
Our recent study9 has taken what has been learned about the
genomics of Barrett’s in recent decades including the high rate of
aneuploidy, increased tissue clonality, and low recurrence of
mutations between patients, to generate a genome-wide statis-
tical approach to risk stratification. This was enabled through the
use of low-cost sequencing technologies ($200 per sample)
directly on the patient samples that were already being collected
and stored. Instead of selecting a single feature to stratify our
patients, we used a method of regression that derived the features
relating to malignant transformation from the data directly. This
means rather than use explicit biomarkers, such as direct
measures of aneuploidy, loss-of-heterozygosity, or clonality, the
effects of these processes were modelled from the patient
genome. In effect, it generated a measure of mutational
complexity that sensitively predicted patient risk without requiring
individual pre-specified biomarkers to be represented in a sample.
More importantly, by classifying the relative risks from the model,
we found that 50% of high-risk patients could be identified ≥8
years before malignant transformation. The closer we got to the
patient developing cancer, the more accurately the model
performed, with 78% identified 2 years prior, and 85% a year
before their diagnosis. Equally, patients with stable genomes
could be classified as low risk within the first 2 years of
surveillance, potentially decreasing the rate of invasive procedures
by more than 50%.
These findings were surprising. The risks appeared to be
independent of the histopathology of the samples, and highly
consistent over many years. Several patterns of progression
appeared to emerge as well: many patients were high risk from
their earliest samples indicating that their Barrett’s was primed to
be malignant (i.e. ‘born bad’); some patients showed evidence of
gradual genomic disorder leading to cancer; and a small number
of patients appeared stable until their final sample, suggesting a
catastrophic genomic change (Fig. 1). Ensuring that this risk model
is accurate across these different patterns of progression will
necessarily involve analysing more patients and evaluating how
these risks relate to the clinical factors that are currently in use. In
this study we used a nested case−control design, which means
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that we matched progressors and non-progressors based on their
demographic and clinical factors such as the length of the Barrett’s
segment. In future it would be interesting to see the extent to
which clinical factors could add to the model. Additional
information from the morphological features obtained by
histopathology could also be included in the model. Merging
these different types of information, always bearing in mind the
clinical feasibility of the approach, will provide more accurate risk
stratification for clinicians and patients to guide decision making.
Barrett’s provides a unique opportunity to analyse a pre-
malignant tissue as it transforms. It may also enable researchers to
look for similar signatures in other cancer types. Our current
understanding of the evolution of most cancers suggests that very
early events often include chromosomal instability. In the case of
some tumours these may be highly specific, as in glioblastoma
where chromosomes 7, 19, or 20 show evidence of early
chromosomal gains. While normal tissues without known malig-
nancies may show a patchwork of cell populations with detectable
mutational and copy number differences.3 As these types of
studies mature and more data across normal and cancer tissues
becomes available, the type of risk classification performed on
Barrett’s tissues will likely be possible for many other cancers.
Completion of the Human Genome Project in 2001 brought
great hopes for an era of medicine informed by an understanding
of genomics. Through the International Cancer Genome Con-
sortium many large sequencing projects since then have been
carried out with the hope of genomics-led diagnostics and
therapeutics.10 All of these have advanced our understanding of
the genomic complexity of cancer; however, for the most part this
has helped only a small subset of patients with specific mutations.
Our recent study offers a practical example of how genomic
medicine can be implemented for early detection.
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Fig. 1 Patterns of progression. Our study suggests that there may be three different genomic patterns of progression: the gradual
accumulation of mutations and copy number rearrangements, increasing a patient’s risk over time; tissues that display high rates of genomic
instability from the earliest samples and throughout surveillance suggesting these tissues are ‘born bad’ or primed to progress; and evidence
that in some patients a catastrophic event may lead to early cancer after a period of genomic stability.
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Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
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